Share price · AUPH
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AUPH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 20 Aug 2026+6.8%
- 6 Aug 2026+6.2%
- 1 Jul 2026-6.9%
Nothing announced by AUPH that day or the session before.
- 25 Jun 2026-5.7%
Nothing announced by AUPH that day or the session before.
- 7 May 2026-6.8%
- 1 Apr 2026+4.4%
Nothing announced by AUPH that day or the session before.
- 4 Mar 2026+6.3%
Nothing announced by AUPH that day or the session before.
- 3 Dec 2025-6.3%
Nothing announced by AUPH that day or the session before.
Share of unusual movement by asset
For each asset, the share of AUPH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Voclosporin(Lupkynis) | Approved | Calcineurin · Cyclophilin A (leading to calcineurin inhibition)Small molecule | Systemic Lupus ErythematosusLupus Nephritis |
| Phase 1/2 | BAFF / APRILProtein / enzyme therapeutic | Systemic Lupus ErythematosusMyasthenia Gravis Generalized Myasthenia Gravis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
March 2029 (1)
What to watch
Financial reports
Quarterly & interim (21)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $84M | $17M | $46M+ $441M short-term inv. | —$46M operating cash flow | report ↗ |
View 20 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $83M | $13M | $180M+ $263M short-term inv. | —$53M operating cash flow | report ↗ |
| 2026-Q1 | $78M | $7.5M | $379M | — | report ↗ |
| 2025-Q4 | $77M | — | $80M+ $318M short-term inv. | —$46M operating cash flow | report ↗ |
| 2025-Q3 | $73M | $8.4M | $73M+ $279M short-term inv. | —$44M operating cash flow | report ↗ |
| 2025-Q2 | $70M | $7.4M | $53M+ $262M short-term inv. | —$44M operating cash flow | report ↗ |
| 2025-Q1 | $62M | $5.7M | $66M+ $246M short-term inv. | —$1.3M operating cash flow | report ↗ |
| 2024-Q4 | $60M | — | $83M+ $275M short-term inv. | —$30M operating cash flow | report ↗ |
| 2024-Q3 | $68M | $3.0M | $37M+ $312M short-term inv. | —$17M operating cash flow | report ↗ |
| 2024-Q2 | $57M | $4.1M | $33M+ $297M short-term inv. | —$16M operating cash flow | report ↗ |
| 2024-Q1 | $50M | $5.5M | $64M+ $255M short-term inv. | $11M-$19M operating cash flow | report ↗ |
| 2023-Q4 | $45M | — | $49M+ $302M short-term inv. | $27M$14M operating cash flow | report ↗ |
| 2023-Q3 | $55M | $14M | $46M+ $292M short-term inv. | $13M-$13M operating cash flow | report ↗ |
| 2023-Q2 | $41M | $13M | $82M+ $269M short-term inv. | $11M-$2.8M operating cash flow | report ↗ |
| 2023-Q1 | $34M | $13M | $89M+ $273M short-term inv. | $26M-$32M operating cash flow | report ↗ |
| 2022-Q4 | $28M | — | $94M+ $295M short-term inv. | $26M$10M operating cash flow | report ↗ |
| 2022-Q3 | $56M | $11M | $86M+ $291M short-term inv. | $9.0M-$15M operating cash flow | report ↗ |
| 2022-Q2 | $28M | $12M | $152M+ $240M short-term inv. | $36M-$28M operating cash flow | report ↗ |
| 2022-Q1 | $22M | $13M | $133M+ $286M short-term inv. | $38M-$47M operating cash flow | report ↗ |
| 2021-Q4 | $23M | — | $232M+ $234M short-term inv. | $33M-$26M operating cash flow | report ↗ |
| 2021-Q3 | $15M | $20M | $58M | $50M-$40M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $283M | $33M | $80M+ $318M short-term inv. | —$136M operating cash flow | report ↗ |
For full-year 2025, Aurinia reported total revenue of $283.06M, up 20.4% YoY, and net income of $287.2M. R&D spend was $32.51M, up 56.4% YoY, while cash and equivalents stood at $80.21M at year-end; no quarterly net burn was disclosed.
The company guided 2026 total revenue to $315M–$325M (up 11%–15% YoY) and LUPKYNIS net product sales to $305M–$315M (up 12%–16% YoY). It also reported progress on aritinercept, having initiated a clinical study in one autoimmune disease and planning another in the first half of 2026, and disclosed a share repurchase of 12.2 million common shares for $98.2 million during 2025.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $235M | $21M | $83M+ $275M short-term inv. | —$44M operating cash flow | report ↗ |
| 2023-FY | $176M | $50M | $49M+ $302M short-term inv. | $20M-$33M operating cash flow | report ↗ |
| 2022-FY | $134M | $45M | $94M+ $295M short-term inv. | $27M-$80M operating cash flow | report ↗ |
| 2021-FY | $46M | $51M | $232M+ $234M short-term inv. | $45M-$158M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 11 purchases ($25.1M), 3 sales ($736K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Robertson Stephen P. · Chief Legal Officer | Open-market sale | 11,867 | $15.97 | $190K | Form 4 |
| 2026-09-10 | Robertson Stephen P. · Chief Legal Officer | Open-market sale | 11,939 | $15.95 | $190K | Form 4 |
| 2026-08-21 | Robertson Stephen P. · Chief Legal Officer | Open-market sale | 20,975 | $16.97 | $356K | Form 4 |
| 2026-06-04 | Bailey Jeffrey Allen · director | Award / grant (derivative) | 23,931 | — | — | Form 4 |
| 2026-06-04 | Nova Tina Susan · director | Award / grant (derivative) | 23,931 | — | — | Form 4 |
| 2026-06-04 | Goetz Kathleen · director | Award / grant (derivative) | 23,931 | — | — | Form 4 |
| 2026-06-04 | Johnson Craig A · director | Award / grant (derivative) | 23,931 | — | — | Form 4 |
| 2026-06-02 | TANG KEVIN; TANG CAPITAL MANAGEMENT LLC · director, Chief Executive Officer, 10% owner; 10% owner | Open-market purchase | 206,005 | $15.28 | $3.1M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 257 reporting institutions held 73.9M shares ($1.1B).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | TANG CAPITAL MANAGEMENT LLC | 12,229,500 | $181.2M |
| 2 | BlackRock, Inc. | 7,845,521 | $116.3M |
| 3 | NEA Management Company, LLC | 3,969,834 | $58.8M |
| 4 | TWO SIGMA INVESTMENTS, LP | 3,428,705 | $50.8M |
| 5 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3,284,368 | $48.7M |
| 6 | STATE STREET CORP | 2,527,099 | $37.5M |
| 7 | MORGAN STANLEY | 2,232,548 | $33.1M |
| 8 | MARSHALL WACE, LLP | 1,874,597 | $27.8M |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 1,663,835 | $24.7M |
| 10 | D. E. Shaw & Co., Inc. | 1,572,983 | $23.3M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1,536,009 | $22.8M |
| 12 | GOLDMAN SACHS GROUP INC | 1,433,508 | $21.2M |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,256,361 | $18.6M |
| 14 | JACOBS LEVY EQUITY MANAGEMENT, INC | 1,097,189 | $16.3M |
| 15 | NOMURA HOLDINGS INC | 968,910 | $14.4M |